BACKGROUND: Significant debate continues over the efficacy of drotrecogin alpha activated (DAA) in sepsis. This updated meta-analysis provides an updated summary effect estimate and explores the reasons for outcome heterogeneity in placebo-controlled randomized clinical trials of DAA on 28-day all-cause mortality in patients with severe sepsis or septic shock. METHODS: Computer searches of MEDLINE, EMBASE, the Cochrane Library, ClinicalTrials.gov, published abstracts from major intensive care meetings and examination of reference lists were used to identify five placebo-controlled randomized clinical trials with 7260 patients. The primary endpoint was 28-day all-cause mortality. Secondary outcomes were 28-day incidence of severe bleeding and intracranial hemorrhage. RESULTS: DAA was not associated with improved 28-day all-cause mortality in patients with severe sepsis or septic shock (pooled relative risk (RR) of 0.97 [95% CI 0.83-1.14]), and is associated with an increase in serious bleeding. The significant heterogeneity in the pooled RR for 28-day mortality (I2 value of 59.4%, χ2 P-value 0.043) is no longer present with exclusion of the post-study amendment portion of PROWESS (I2 value of 0%, χ2 P-value 0.44 without PROWESS post-amendment). Using meta-regression, the best ranked predictor of outcome heterogeneity was baseline mortality in the placebo arm, which was among the highest in PROWESS. CONCLUSION: DAA is not associated with improved survival in patients with severe sepsis or septic shock. Further studies should be done to determine whether changes in supportive therapy for sepsis explain the variable efficacy of DAA in randomized controlled clinical trials observed over time.
BACKGROUND: Significant debate continues over the efficacy of drotrecogin alpha activated (DAA) in sepsis. This updated meta-analysis provides an updated summary effect estimate and explores the reasons for outcome heterogeneity in placebo-controlled randomized clinical trials of DAA on 28-day all-cause mortality in patients with severe sepsis or septic shock. METHODS: Computer searches of MEDLINE, EMBASE, the Cochrane Library, ClinicalTrials.gov, published abstracts from major intensive care meetings and examination of reference lists were used to identify five placebo-controlled randomized clinical trials with 7260 patients. The primary endpoint was 28-day all-cause mortality. Secondary outcomes were 28-day incidence of severe bleeding and intracranial hemorrhage. RESULTS:DAA was not associated with improved 28-day all-cause mortality in patients with severe sepsis or septic shock (pooled relative risk (RR) of 0.97 [95% CI 0.83-1.14]), and is associated with an increase in serious bleeding. The significant heterogeneity in the pooled RR for 28-day mortality (I2 value of 59.4%, χ2 P-value 0.043) is no longer present with exclusion of the post-study amendment portion of PROWESS (I2 value of 0%, χ2 P-value 0.44 without PROWESS post-amendment). Using meta-regression, the best ranked predictor of outcome heterogeneity was baseline mortality in the placebo arm, which was among the highest in PROWESS. CONCLUSION:DAA is not associated with improved survival in patients with severe sepsis or septic shock. Further studies should be done to determine whether changes in supportive therapy for sepsis explain the variable efficacy of DAA in randomized controlled clinical trials observed over time.
Authors: David Moher; Sally Hopewell; Kenneth F Schulz; Victor Montori; Peter C Gøtzsche; P J Devereaux; Diana Elbourne; Matthias Egger; Douglas G Altman Journal: BMJ Date: 2010-03-23
Authors: V Marco Ranieri; B Taylor Thompson; Philip S Barie; Jean-François Dhainaut; Ivor S Douglas; Simon Finfer; Bengt Gårdlund; John C Marshall; Andrew Rhodes; Antonio Artigas; Didier Payen; Jyrki Tenhunen; Hussein R Al-Khalidi; Vivian Thompson; Jonathan Janes; William L Macias; Burkhard Vangerow; Mark D Williams Journal: N Engl J Med Date: 2012-05-22 Impact factor: 91.245
Authors: Marcel Schouten; Cornelis van 't Veer; Joris J T H Roelofs; Bruce Gerlitz; Brian W Grinnell; Marcel Levi; Tom van der Poll Journal: Thromb Haemost Date: 2011-09-08 Impact factor: 5.249
Authors: Alvaro Castellanos-Ortega; Borja Suberviola; Luis A García-Astudillo; María S Holanda; Fernando Ortiz; Javier Llorca; Miguel Delgado-Rodríguez Journal: Crit Care Med Date: 2010-04 Impact factor: 7.598
Authors: Jean-Francois Dhainaut; Massimo Antonelli; Patrick Wright; Arnaud Desachy; Jean Reignier; Sylvain Lavoue; Julien Charpentier; Mark Belger; Michael Cobas-Meyer; Cornelia Maier; Mariano A Mignini; Jonathan Janes Journal: Intensive Care Med Date: 2009-03-05 Impact factor: 17.440
Authors: David F Gaieski; Mark E Mikkelsen; Roger A Band; Jesse M Pines; Richard Massone; Frances F Furia; Frances S Shofer; Munish Goyal Journal: Crit Care Med Date: 2010-04 Impact factor: 7.598
Authors: Andrew F Shorr; Jonathan M Janes; Antonio Artigas; Jyrki Tenhunen; Duncan L A Wyncoll; Emmanuelle Mercier; Bruno Francois; Jean-Louis Vincent; Burkhard Vangerow; Darell Heiselman; Amy G Leishman; Yajun E Zhu; Konrad Reinhart Journal: Crit Care Date: 2010-12-21 Impact factor: 9.097
Authors: Mitchell M Levy; R Phillip Dellinger; Sean R Townsend; Walter T Linde-Zwirble; John C Marshall; Julian Bion; Christa Schorr; Antonio Artigas; Graham Ramsay; Richard Beale; Margaret M Parker; Herwig Gerlach; Konrad Reinhart; Eliezer Silva; Maurene Harvey; Susan Regan; Derek C Angus Journal: Intensive Care Med Date: 2010-01-13 Impact factor: 17.440